Last reviewed · How we verify
VISIPAQUE 270
Visipaque 270 is a non-ionic, iso-osmolar contrast medium that provides radiographic visualization of blood vessels and organs during diagnostic imaging procedures.
Visipaque 270 is a non-ionic, iso-osmolar contrast medium that provides radiographic visualization of blood vessels and organs during diagnostic imaging procedures. Used for Coronary angiography and left ventriculography, Peripheral vascular angiography, Cerebral angiography.
At a glance
| Generic name | VISIPAQUE 270 |
|---|---|
| Also known as | Iodixanol Injection |
| Sponsor | Bracco Diagnostics, Inc |
| Drug class | Non-ionic iso-osmolar contrast medium |
| Modality | Small molecule |
| Therapeutic area | Diagnostic Imaging |
| Phase | FDA-approved |
Mechanism of action
Visipaque 270 contains iodixanol, an osmotically balanced contrast agent with an osmolality of approximately 290 mOsm/kg, matching that of blood and cerebrospinal fluid. The iodine content (270 mg/mL) attenuates X-rays, allowing enhanced visualization of vascular and organ structures during angiography, coronary angiography, and other radiographic procedures. Its iso-osmolar formulation is designed to minimize osmotic stress on tissues and reduce the risk of contrast-induced nephropathy compared to hyperosmolar agents.
Approved indications
- Coronary angiography and left ventriculography
- Peripheral vascular angiography
- Cerebral angiography
- Renal angiography
- Aortography
Common side effects
- Contrast-induced nephropathy
- Hypersensitivity reactions
- Nausea and vomiting
- Flushing and warmth sensation
- Arrhythmias
Key clinical trials
- Evaluation of the Efficacy of Suprascapular Nerve Block in Adhesive Capsulitis (NA)
- Post-Marketing Safety Study in ST-Segment Elevation Myocardial Infarction (STEMI) Participants Undergoing Primary Percutaneous Coronary Intervention (PCI) Procedure With VISIPAQUE® as the Contrast Medium
- Aortic Stenosis Pre-Transcatheter Aortic Valve Replacement (TAVR) Procedure CT Scan (NA)
- Pulmonary Interstitial Lymphography in Early Stage Lung Cancer (NA)
- Comparison of Contrast Agents During CT Angiography (NA)
- DynaCT in Preoperative Imaging Before Insertion of Stentgraft (NA)
- Isovue in Peripheral Digital Subtraction Angiography (DSA) (PHASE4)
- A Clinical Study of Xenetix 300 in Multislice Computed Tomography (CT) Pediatric Indications (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VISIPAQUE 270 CI brief — competitive landscape report
- VISIPAQUE 270 updates RSS · CI watch RSS
- Bracco Diagnostics, Inc portfolio CI